Gentamicin, sisomicin, tobramycin, and kanamycin were compared in parallel tests in vitro and in vivo against a variety of bacterial strains and species. A number of differences were seen in vitro, in particular: (i) the lower activity of kanamycin, (ii) the greater activity of tobramycin against Pseudomonas, (iii) the greater activity of gentamicin and sisomicin against Serratia, and (iv) the generally similar results with tobramycin, gentamicin, and sisomicin against species other than Pseudomonas and Serratia, with the ranking in order of decreasing activity being sisomicin, gentamicin, and tobramycin. Analysis of disc test results suggested that the gentamicin disc is not adequate for testing the susceptibility of all bacteria to sisomicin or tobramycin. In vivo tests did not confirm all specifics of in vitro tests; results of in vivo tests indicated that sisomicin may be the most active. It is suggested that the place of each of the antibiotics in human therapy can best be evaluated by more rigorous in vivo tests and clinical studies rather than extensive in vitro comparisons.
The introduction of new, useful aminoglycoside antibiotics has progressed at a modest pace. Today, the most commonly used parenteral aminoglycoside antibiotics are kanamycin and gentamicin. Recently, two additional potentially useful parenteral aminoglycoside antibiotics have been described. These are tobramycin and sisomicin. Structures have been published for kanamycin (11) , gentamicin (4), tobramycin (7) , and sisomicin (3) . Many published laboratory studies have compared gentamicin with kanamycin, and some have compared gentamicin with sisomicin (13) or gentamicin with tobramycin (5, (8) (9) (10) 12) . Few studies, however, have involved a comparative evaluation of the four aminoglycoside antibiotics in parallel tests. Such a study is the subject of this report.
MATERIALS AND METHODS
Gentamicin, sisomicin, and kanamycin were used in the form of the sulfate, whereas tobramycin was used as the base; all values are corrected in terms of the base. Tobramycin was obtained from Eli Lilly & Co., and kanamycin was obtained from Bristol Laboratories. For reference purposes, carbenicillin (Beecham Inc.) and polymyxin B sulfate (Pfizer Inc.) were used. The strains of bacteria utilized in the study were from a variety of sources, but in all cases represent recent clinical isolates. Identification of all strains was confirmed by usual biochemical test procedures (2) .
Disc tests. Disc susceptibility tests were done with commercially available 10-,ug gentamicin discs and 30-p&g kanamycin discs. The 10-,ug sisomicin discs were prepared for use by BBL; 10-pg tobramycin discs were prepared in our laboratory. The disc test procedure used was identical to that conventionally known as the Bauer-Kirby procedure (1, 6) . MuellerHinton agar (BBL) was used in plastic disposable petri dishes (Falcon Plastics).
Broth dilution tests. Broth dilution tests were done in Mueller-Hinton broth (BBL) in a volume of 3 ml/tube with an inoculum of approximately 5 X 104 to 1 X 101 organisms. This inoculum was obtained by appropriate dilution of an 18-hr broth culture (0.05 ml of a 1:1,000 dilution). For broth dilution tests, stock concentrations were freshly prepared in sterile distilled water and added to 100-ml quantities of broth to obtain twofold dilutions of antibiotic concentrations based on 1 pg/ml. These concentrations ranged from 0.03 to 256 pg/ml in terms of the base. Tubes were read visually after incubation for 18 to 24 hr at 37 C. Tests with Mycoplasma were done in PPLO broth with added serum and yeast extract; end points were determined by streaking on PPLO agar.
In vivo tests. Mouse protection tests were done in male CF-I mice weighing approximately 20 g each, in treatment groups of seven each at five to seven dose levels with 10 Table 2 , for other gram-negative bacteria in Table 3 , and for Mycoplasma in Table 4 .
Gentamicin, sisomicin, and tobramycin had a similar high degree of activity against Staphylococcus, with gentamicin and sisomicin being slightly more active than tobramycin in terms of levels required to inhibit all strains ( The data for Escherichia coli (Table 3) show gentamicin and tobramycin to have similar activity against the E. coli strains; sisomicin was slightly more active, and kanamycin was less active than the other three aminoglycosides. With Klebsiella strains (Table 3) , sisomicin appeared more active against a higher number of strains than either gentamicin or tobramycin, with only small differences noted between gentamicin and tobramycin. As with the E. coli strains, Klebsiella strains were less susceptible to kanamycin than to the other three aminoglycosides.
Although the number of strains studied was small, Serratia strains (Table 3) showed a difference in susceptibility to the several aminoglycoside antibiotics. These strains were most highly susceptible to sisomicin and gentamicin, with lesser susceptibility to tobramycin and kanamycin. Sisomicin appeared to be more active than gentamicin with the small number of strains were essentially limited to Pseudomonas, for which tobramycin consistently gave larger zone sizes than either sisomicin or gentamicin, whereas Klebsiella and Proteus tended to give larger zones with sisomicin, gentamicin, and kanamycin.
Interrelationship of disc tests. Recent regulatory decisions (6) have suggested the preference for a single disc serving for the evaluation of susceptibility of organisms to a group of antibiotics. With this in mind, we compared the zone sizes for gentamicin, sisomicin, and tobramycin for 334 strains (Table 6 ). Shown are the mean zone sizes against each group of pathogens. Correlation coefficients (R) were calculated showing the degree of association (from -1.0 to +1.0) for each pair (sisomicin-gentamicin, tobramycin-gentamicin), as were regression equations needed to estimate the sisomicin or tobramycin zonal response when the gentamicin disc was used. As an example, the correlation coefficient between gentamicin and sisomicin zone sizes for 43 strains of S. aureus was 0.91. The sisomicin zonal response for a Staphylococcus strain can be estimated by adding 3.93 to 0.85 times the gentamicin zone size. Correlation coefficients between gentamicin and sisomicin averaged 0.94 for all organisms and were higher than correlation coefficients between gentamicin and tobramycin. The latter was 0.58 for all organisms but was 0.87 when Pseudomonas was deleted. Low correlation coefficients were seen between gentamicin and sisomicin for enterococci and Serratia strains, whereas low values were seen between gentamicin and tobramycin for streptococci, enterococci, Pseudomonas, and Serratia. These findings suggest the need for individual susceptibility discs for each of these antibiotics.
In vivo activity. The comparative in vivo activity of the four aminoglycosides was studied in parallel protection tests in mice (Table 7) . With all antibiotics, inspection of the ratios of PD50 to PDgo suggests that the slopes of responses are not the same. A general summarization of the data would suggest that sisomicin is the most highly active in vivo, followed by gentamicin, tobramycin, and kanamycin, although the differential activity between gentamicin and tobramycin is in many cases minimal. The striking in vitro difference in susceptibility of Pseudomonas strains to tobramycin, relative to gentamicin and sisomicin, was not demonstrated in vivo. In each instance, sisomicin was the most highly active, followed by tobramycin and gentamicin.
DISCUSSION
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9 (100) 2 (100) 1 (100) 1 (100) 9 (100) 1 (100) It is clear from the analysis of the zonal response of a number of strains that separate discs will be required for each of the antibiotics, at least with regard to the Bauer-Kirby susceptibility method.
In vivo tests did not support all of the differences seen with in vitro tests, although the number of strains studied was small. Sisomicin was clearly the most active in vivo, even against Pseudomonas strains. These in vivo differences may well reflect absorption differences.
With specific attention to the overall comparative activity of the four aminoglycosides studied, in vitro tests would lead to the conclusion that tobramycin is most 
